Home › All Companies › ASRT

Assertio Holdings, Inc. (ASRT)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-05-13

Key Insights

  • Assertio Holdings has agreed to be acquired by Zydus Worldwide DMCC for $23.50 per share in an all-cash transaction, with the Board unanimously approving the merger and recommending stockholder acceptance.
  • The acquisition is structured as a tender offer followed by merger under Delaware law, with Purchaser required to commence the offer within 5 business days and initial expiration at 20 business days, providing a defined timeline for completion.
  • Closing is contingent on achieving at least 50% + 1 share tendered, maintaining minimum closing net cash of $95 million, and regulatory approval, with no financing condition required from Parent, reducing execution risk.
  • All equity compensation including stock options and restricted stock units will be converted to cash payments at closing, with vested/in-the-money options receiving spread value and all RSUs receiving the full $23.50 per share consideration.
Sentiment: Positive Significance: 10/10
View Original Filing →
Current Report Filed: 2026-05-08

Key Insights

  • Assertio agreed with Garda Therapeutics to extend the tender offer deadline from an unspecified earlier date to May 14, 2026, suggesting potential delays or negotiations in the previously announced merger agreement dated May 1, 2026.
  • The merger involves Garda Therapeutics acquiring Assertio through a subsidiary (Audi Merger Sub, Inc.), indicating a significant corporate restructuring event that could materially impact shareholder value and company operations.
  • This extension was announced via Regulation FD disclosure, meaning the information is furnished but not filed under Section 18, limiting its legal liability implications but confirming the material nature of the tender offer deadline change.
Sentiment: Neutral Significance: 6/10
View Original Filing →
Quarterly Report Filed: 2026-05-08

Key Insights

  • The filing shows Q1 2026 results for a specialty pharmaceutical company with multiple product lines including ROLVE DON, INDOCIN, Sympaza, and SPRIX Nasal Spray, indicating an established portfolio but limited financial detail in the provided excerpt.
  • The company has convertible senior notes (6.5%) outstanding as of March 31, 2026, representing a significant debt obligation that could impact equity value through conversion or cash requirements.
  • Recent subsequent events noted in April-May 2026 include product disposal activities and litigation matters (New York Action settled April 30, 2026), suggesting operational restructuring and potential legal liabilities resolution.
  • The presence of multiple litigation matters (Derivative Litigation, Jung Litigation, New York Action) indicates ongoing legal risks that could materially impact financial position and require continued monitoring.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Current Report Filed: 2026-04-29

Key Insights

  • Assertio Holdings is undergoing a merger with Garda Therapeutics, with the tender offer deadline extended to May 4, 2026, suggesting potential delays or conditions that required negotiated extension from the original timeline.
  • The merger agreement was originally dated April 8, 2026, and the extension announcement on April 29 indicates the tender offer commencement was delayed by approximately 3 weeks, which may signal regulatory hurdles, financing conditions, or shareholder approval challenges.
  • This is a Regulation FD disclosure (non-material event notification), meaning the SEC does not consider this extension announcement to be material information requiring standard filing status, suggesting routine merger logistics rather than unexpected complications.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Current Report Filed: 2026-04-21

Key Insights

  • Garda Therapeutics is commencing a tender offer on April 29, 2026, to acquire all outstanding shares of Assertio Holdings, representing a material merger event that will significantly impact shareholder ownership and the company's independence.
  • The tender offer follows a 20-day 'window-shop' period that expired on April 28, 2026, allowing Assertio to solicit alternative proposals before Garda's formal offer, which is a standard protective mechanism for shareholders in merger transactions.
  • This 8-K filing provides formal disclosure of the previously announced Merger Agreement dated April 8, 2026, signaling that the transaction is progressing as planned toward completion with institutional approval and regulatory oversight.
Sentiment: Neutral Significance: 8/10
View Original Filing →
Current Report Filed: 2026-04-14

Key Insights

  • Assertio Holdings, Inc. (ASRT) has completed the sale of its INDOCIN®, SPRIX®, SYMPAZAN®, CAMBIA®, ZIPSOR®, and OTREXUP® product franchises to Cosette Pharmaceuticals, Inc. for $35 million in cash with potential for additional deferred milestone payments.
  • The divestiture of these non-core product franchises aligns with Assertio's strategic focus and allows the company to streamline its operations and concentrate on its key growth initiatives.
  • The unaudited pro forma financial statements provided with the 8-K filing indicate the potential financial impact of the asset sale on Assertio's balance sheet and income statement.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-04-09

Key Insights

  • Assertio Holdings, Inc. (ASRT) has entered into an agreement to be acquired by Garda Therapeutics, Inc. for $18.00 per share in cash plus one contingent value right (CVR) per share.
  • The merger is subject to customary closing conditions, including a minimum tender of over 50% of ASRT's outstanding shares and a minimum closing net cash balance of $115 million.
  • The transaction will provide ASRT shareholders with liquidity and an opportunity to receive additional cash payments through the CVR agreement, pending achievement of certain milestones.
Sentiment: Positive Significance: 8/10
View Original Filing →
Current Report Filed: 2026-03-16

Key Insights

  • Assertio Holdings, Inc. reported its Q4 2025 and full-year 2025 financial results, indicating the company's performance for the period.
  • The filing does not mention any material agreements, leadership changes, or earnings surprises that would be considered significant news for investors.
  • Without additional details on the company's financial performance, it is difficult to assess the overall sentiment and significance of this 8-K filing.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Annual Report Filed: 2026-03-16

Key Insights

  • Assertio Holdings' FY 2025 revenue is projected to be $0.0667, flat compared to the prior year.
  • The company's other assets and liabilities remained relatively stable from 2024 to 2025.
  • Assertio's cost and expenses appear to be well-controlled, with consistent year-over-year trends.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-02-10

Key Insights

  • Ajay Patel, the EVP and CFO of Assertio Holdings, Inc. (ASRT), exercised 1,666 restricted stock units and disposed of 825 shares to cover tax withholdings, indicating an ongoing commitment to the company.
  • The reporting of the transaction in the SEC Form 4 filing suggests transparency and compliance with regulatory requirements around insider transactions.
  • The adjustments to the share amounts to reflect a 1-for-15 reverse stock split indicate the company has taken steps to manage its capital structure.
Sentiment: Positive Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-02-10

Key Insights

  • The reporting person, Paul Schwichtenberg, is the President and COO of Assertio Holdings, Inc. (ASRT), indicating he is a key insider with decision-making authority.
  • Schwichtenberg exercised 1,666 restricted stock units and sold 825 shares to cover tax withholding, suggesting he is selectively monetizing his equity compensation.
  • After the reported transactions, Schwichtenberg still holds 12,009 shares of ASRT common stock, suggesting he maintains a significant equity stake in the company.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Current Report Filed: 2026-01-12

Key Insights

  • Assertio Holdings has regained compliance with Nasdaq's minimum bid price requirement, allowing the company to continue listing on the Nasdaq Capital Market.
  • The regaining of compliance indicates that Assertio has successfully addressed any previous issues related to its stock price, which is a positive signal for investors.
  • The 8-K filing provides a timely update on Assertio's compliance status, demonstrating the company's commitment to transparency and adherence to market regulations.
Sentiment: Positive Significance: 5/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.